Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PRIDE
- 31 May 2013 Primary endpoint 'Objective-clinical-response-rate' has not been met.
- 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History